DVHGF
Devonian Health Group Inc.
1W: +0.0%
1M: +0.0%
3M: +14878.9%
YTD: +149.4%
1Y: +7308.7%
$10.65
+0.00 (+0.00%)
After Hours: $9.29 (-1.37, -12.82%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$29.5M
52W Range4.266-10.8
Volume100
Avg Volume1
Beta1.48
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAndre Boulet
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date2022-09-19
Websitegroupedevonian.com
360, rue des Entrepreneurs
Québec, QC G5V 4T1
CA
Québec, QC G5V 4T1
CA
About Devonian Health Group Inc.
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Latest News
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
Devonian Health Group Announces Grant of Stock Options
Recent Insider Trades
No insider trades found